J&J's Big Layoff Shakeup: Is It Cost-Cutting or Strategic Realignment?

 

Hey everyone! Here’s the scoop: Johnson & Johnson (JNJ) has been making waves with some pretty significant layoffs in China. Reports are saying they’ve laid off around 20% of their staff in the surgical division, and the compensation packages range from N+1 to N+3. This move is part of a broader restructuring, and while J&J hasn’t officially commented yet, the news has definitely been causing a stir. Interestingly, this isn't the first time they've downsized; they've had multiple rounds of layoffs over the past couple of years, especially since the company restructured and spun off its consumer health division (now known as Kenvue, ticker: KVUE).

 

J&J recently reported solid revenue growth, but the profit took a significant hit—down by nearly 38% in Q3. So, even though they’re making more money, the bottom line isn’t looking as great, which might explain some of these restructuring moves. When you break it down by region, the U.S. is J&J’s major revenue driver, making up about 57% of their income, while their Asia-Pacific and non-U.S. markets saw a slight increase of 0.5% to $3.475 billion, accounting for 15.5% of their overall revenue.

 

It’s also worth noting that J&J isn’t alone in this. 2024 has seen a wave of layoffs in the multinational medical device industry. Companies like Medtronic (MDT) and Becton Dickinson (BDX) are also trimming down staff, and it seems like a growing trend. The reason? Well, a lot of it has to do with the global economic uncertainty and the changing healthcare landscape. With the U.S. cutting interest rates, many companies are bracing for a potential economic slowdown and trying to protect themselves in advance. The truth is, they’re not just cutting costs—they’re also realigning strategies and shoring up their positions for what could be a bumpy ride ahead.

 

Medical strategy consultant Qin Wangcen weighed in on this, saying that the global market is generally in a weak economic cycle right now, and with all the international uncertainties, many companies are very sensitive to the economic shifts caused by the U.S. rate cuts. They’re taking early steps to hedge their risks. In addition, the future impact of U.S. healthcare negotiations will also be a key factor in the global pharmaceutical market. But, according to Qin, the layoffs we’re seeing now are unlikely to have a big impact—at least not in the short term. The long-term effects, though? That’s still up in the air.

 

Given these dynamics, it’s clear that J&J’s layoffs aren’t just about cost-cutting. The company is also undergoing a strategic shift, with an increased focus on expanding its medical technology and pharmaceutical sectors. This means resources may be reallocated away from other divisions, including surgical instruments, as part of a broader push to strengthen their core growth areas.

 

 

Now, the comments section has some pretty interesting takes on all this. Some people are linking these layoffs to Robert F. Kennedy Jr.'s recent appointment as the U.S. health secretary. One user commented, “This little Kennedy has too much power”, suggesting that Kennedy’s influence has led to a drop in vaccine stocks and, by extension, the layoffs. The idea is that companies like J&J might be reacting to shifts in U.S. healthcare policies. On the other hand, there are users who see the silver lining in these layoffs, with one commenter saying, “Getting laid off with N+3? That’s like getting paid to leave. I’d take it!” It’s definitely a mixed bag—while some are focusing on the potential long-term impacts of Kennedy’s influence, others are just glad to see the generous severance packages.

 

 

As for J&J’s stock price, it’s been hovering around $154 recently, but it took a hit last Thursday, possibly due to its latest financial report. However, it bounced back by Friday, showing that the market’s reaction is a bit unpredictable.

 

So, what do you think about all this?